MILAN--(BUSINESS WIRE)--Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced CE Mark approval and commercial launch for a comprehensive new range of pacing, defibrillation and left ventricular leads. Designed for safety and long term reliability, TILDA pacing leads, VIGILA defibrillation leads and CELERITY left ventricular lead families1 offer multiple implant options to accommodate patients’ needs and physicians’ preferences.
